Isthmus Partners LLC reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 75.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,737 shares of the medical equipment provider’s stock after selling 32,737 shares during the period. Isthmus Partners LLC’s holdings in Lantheus were worth $1,069,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Nisa Investment Advisors LLC grew its holdings in shares of Lantheus by 15.8% in the third quarter. Nisa Investment Advisors LLC now owns 8,300 shares of the medical equipment provider’s stock worth $826,000 after purchasing an additional 1,134 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Lantheus in the third quarter worth $41,000. State of Alaska Department of Revenue increased its stake in shares of Lantheus by 47.0% in the third quarter. State of Alaska Department of Revenue now owns 9,380 shares of the medical equipment provider’s stock worth $932,000 after buying an additional 3,000 shares during the period. Diversified Management Inc. purchased a new position in shares of Lantheus in the third quarter worth $375,000. Finally, GAMMA Investing LLC raised its holdings in Lantheus by 3.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,457 shares of the medical equipment provider’s stock valued at $344,000 after buying an additional 109 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.
Lantheus Price Performance
Shares of LNTH stock opened at $100.10 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. Lantheus Holdings, Inc. has a fifty-two week low of $50.15 and a fifty-two week high of $111.86. The firm has a market cap of $6.54 billion, a P/E ratio of 24.18 and a beta of -0.06. The business’s 50 day moving average price is $100.32 and its 200-day moving average price is $98.58.
Lantheus (NASDAQ:LNTH – Get Free Report) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same quarter in the prior year, the company earned $1.57 earnings per share. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.
Analysts Set New Price Targets
LNTH has been the subject of several analyst reports. Mizuho reissued a “neutral” rating and set a $109.00 price target (down from $115.00) on shares of Lantheus in a research report on Tuesday, October 13th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price objective for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. B. Riley Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $125.00 to $102.50 in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat, Lantheus presently has an average rating of “Hold” and a consensus target price of $107.44.
View Our Latest Analysis on LNTH
Lantheus Company Profile
Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.
The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.
See Also
- Five stocks we like better than Lantheus
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
